Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells
Cell Proliferation · 2025
DOI: 10.1111/cpr.13771 ↗At a glance
Journal article in Cell Proliferation, 2025. Written by Jonathan Nissenbaum and 10 co-authors. Institution: NewStem LTD, Jerusalem, Israel. Major MEDLINE topics: Paclitaxel, Carboplatin, Drug Resistance, Neoplasm, Human Embryonic Stem Cells. Cited 1 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: NewStem LTD, Azrieli Foundation, Israel Science Foundation.
Abstract (original language)
Taxanes and platinum molecules, specifically paclitaxel and carboplatin, are widely used anticancer drugs that induce cell death and serve as first‐line chemotherapy for various cancer types. Despite the efficient effect of both drugs on cancer cell proliferation, many tumours have innate resistance against paclitaxel and carboplatin, which leads to inefficient treatment and poor survival rates. Haploid human embryonic stem cells (hESCs) are a novel and robust platform for genetic screening. To gain a comprehensive view of genes that affect or regulate paclitaxel and carboplatin resistance, genome‐wide loss‐of‐function screens in haploid hESCs were performed. Both paclitaxel and carboplatin screens have yielded selected plausible gene lists and pathways relevant to resistance prediction. The effects of mutations in selected genes on the resistance to the drugs were demonstrated. Based on the results, an algorithm that can predict resistance to paclitaxel or carboplatin was developed. Applying the algorithm to the DNA mutation profile of patients' tumours enabled the separation of sensitive versus resistant patients, thus, providing a prediction tool. As the anticancer drugs arsenal can offer alternatives in case of resistance to either paclitaxel or carboplatin, an early prediction can provide a significant advantage and should improve treatment. The algorithm assists this unmet need and helps predict whether a patient will respond to the treatment and may have an immediate clinically actionable application.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- NewStem LTD, Jerusalem, Israel.
- The Azrieli Center for Stem Cells and Genetic Research, Department of Genetics, Silberman Institute of Life Sciences, The Hebrew University, Jerusalem, Israel.
- Hadassah Stem Cell Research Center, Goldyne Savad Institute of Gene Therapy, Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- The Center for Genomic Technologies, The Hebrew University, Jerusalem, Israel.
ORCID profiles: Nissim Benvenisty
Funding
- NewStem LTD
- Azrieli Foundation
- Israel Science Foundation
- ISF-Israel Precision Medicine Partnership (IPMP) Program
Cite
APA
Nissenbaum, J., Segal, E., Philip, H., Cashman, R., Golan-Lev, T., Reubinoff, B. E., Turjeman, A., Yanuka, O., Lezmi, E., Kopper, O., & Benvenisty, N. (2025). Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells. Cell Proliferation. https://doi.org/10.1111/cpr.13771
Vancouver
Nissenbaum J, Segal E, Philip H, Cashman R, Golan-Lev T, Reubinoff BE, et al. Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells. Cell Proliferation. 2025. doi:10.1111/cpr.13771
BibTeX
@article{Nissenbaum2025,
author = {Nissenbaum, Jonathan and Segal, Emanuel and Philip, Hagit and Cashman, Rivki and Golan-Lev, Tamar and Reubinoff, Benjamin E and Turjeman, Adi and Yanuka, Ofra and Lezmi, Elyad and Kopper, Oded and Benvenisty, Nissim},
title = {Predicting tumour resistance to paclitaxel and carboplatin utilising genome‐wide screening in haploid human embryonic stem cells},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.13771}
}
EUVIMED